## STROBE Statement—Checklist of items that should be included in reports of cohort studies

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1  
(a) Indicate the study’s design with a commonly used term in the title or the abstract Y  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found Y |
| **Introduction** | 2  
Explain the scientific background and rationale for the investigation being reported Y |
| **Objectives** | 3  
State specific objectives, including any prespecified hypotheses Y |
| **Methods** | 4  
Present key elements of study design early in the paper Y |
| **Study design** | 5  
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Y |
| **Setting** | 6  
(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Y  
(b) For matched studies, give matching criteria and number of exposed and unexposed Y |
| **Participants** | 7  
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Y |
| **Variables** | 8*  
For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Y |
| **Data sources/measurement** | 9  
Describe any efforts to address potential sources of bias Y |
| **Bias** | 10  
Explain how the study size was arrived at Y |
| **Study size** | 11  
Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Y |
| **Quantitative variables** | 12  
(a) Describe all statistical methods, including those used to control for confounding Y  
(b) Describe any methods used to examine subgroups and interactions Y  
(c) Explain how missing data were addressed Y  
(d) If applicable, explain how loss to follow-up was addressed NA  
(e) Describe any sensitivity analyses NA |
| **Statistical methods** | 13*  
(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Y  
(b) Give reasons for non-participation at each stage NA  
(c) Consider use of a flow diagram NA |
| **Results** | 14*  
(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Y  
(b) Indicate number of participants with missing data for each variable of interest Y  
(c) Summarise follow-up time (eg, average and total amount) Y |
| **Descriptive data** | 15*  
Report numbers of outcome events or summary measures over time Y |
| **Outcome data** | 16  
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Y |
(b) Report category boundaries when continuous variables were categorized Y  
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period NA  

| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Y |

**Discussion**

| Key results | 18 | Summarise key results with reference to study objectives Y |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Y |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Y |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results Y |

**Other information**

| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Y |

*Give information separately for exposed and unexposed groups.